Guidelines

Male Contraception: Why are options so limited, and what's next?

The World Health Organization has published target product profiles for male contraceptive methods, detailing the efficacy, safety, and user attributes required for future development.

Tactical athletes need more than a sports physical

New recommendations address cardiovascular screening and management for tactical athletes, focusing on unique physiological demands and risk factors in this population.

Pulmonary alveolar proteinosis: Your patients deserve better

Pulmonary alveolar proteinosis (PAP) management across Europe faces significant disparities, driven by varied access to diagnostic tools and treatment modalities. A unified approach is critical for improving patient outcomes.

ICD-11: What European GPs need to know about the new classification system

The ICD-11 system introduces significant changes to disease classification, impacting coding for conditions like hidradenitis suppurativa and neonatal encephalopathy.

Duke-ISCVID 2023: What changed for endocarditis diagnosis at the bedside?

The 2023 Duke-ISCVID criteria update refined diagnostic pathways for infective endocarditis, integrating advanced imaging and microbiological techniques to improve accuracy.

Navigating dental trauma in children: How guidelines handle the immature apex

Managing dental trauma in children with immature apices presents unique challenges, requiring careful consideration of pulp vitality and root development.

Lupus Nephritis: How Low Can Steroid Doses Go?

Lower-dose steroid regimens in lupus nephritis are increasingly favored, balancing efficacy against the substantial burden of glucocorticoid toxicity.

Lower-dose steroids in lupus nephritis: How far has guidance truly moved?

Guideline recommendations for lupus nephritis have shifted towards lower-dose steroid regimens, aiming to balance efficacy with reduced toxicity.

Antihistamine-refractory urticaria: when standard care falls short

Current guidelines for chronic urticaria recommend step-up therapy for patients who do not respond to standard antihistamine doses, escalating to higher doses or adding biologics.